ASC-J9
new
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407256

CAS#: 52328-98-0

Description: ASC-J9, also known as GO-Y025 and Dimethylcurcumin, is an AR degradation enhancer ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway.ASC-J9 treatment enhanced BCG efficacy to suppress bladder cancer cell proliferation via increasing the recruitment of monocytes/macrophages that involved the promotion of BCG attachment/internalization to the bladder cancer cells through increased integrin-α5β1 expression and IL6 release.


Price and Availability

Size Price Shipping out time Quantity
100mg USD 850 2 Weeks
200mg USD 1450 2 Weeks
500mg USD 2250 2 Weeks
1g USD 3250 2 Weeks
2g USD 4950 2 Weeks
5g USD 6950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-22. Prices are subject to change without notice.

ASC-J9, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 407256
Name: ASC-J9
CAS#: 52328-98-0
Chemical Formula: C23H24O6
Exact Mass: 396.1573
Molecular Weight: 396.439
Elemental Analysis: C, 69.68; H, 6.10; O, 24.21


Synonym: ASC-J9; ASC J9; GO-Y025; GO-Y 025; GO Y025; Dimethylcurcumin.

IUPAC/Chemical Name: (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one

InChi Key: ZMGUKFHHNQMKJI-CIOHCNBKSA-N

InChi Code: InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-15,24H,1-4H3/b9-5+,10-6+,18-15-

SMILES Code: O=C(/C=C(O)/C=C/C1=CC=C(OC)C(OC)=C1)/C=C/C2=CC=C(OC)C(OC)=C2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Shang Z, Li Y, Zhang M, Tian J, Han R, Shyr CR, Messing E, Yeh S, Niu Y, Chang C. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression. Mol Cancer Ther. 2015 Nov;14(11):2586-94. doi: 10.1158/1535-7163.MCT-14-1055-T. Epub 2015 Aug 11. PubMed PMID: 26264279; PubMed Central PMCID: PMC4704455.

2: Yamashita S, Arai Y. [ASC-J9 for castration-resistant prostate cancer]. Nihon Rinsho. 2014 Dec;72(12):2126-9. Japanese. PubMed PMID: 25518345.

3: Verderio P, Pandolfi L, Mazzucchelli S, Marinozzi MR, Vanna R, Gramatica F, Corsi F, Colombo M, Morasso C, Prosperi D. Antiproliferative effect of ASC-J9 delivered by PLGA nanoparticles against estrogen-dependent breast cancer cells. Mol Pharm. 2014 Aug 4;11(8):2864-75. doi: 10.1021/mp500222k. Epub 2014 Jul 18. PubMed PMID: 24945469.

4: He D, Li L, Zhu G, Liang L, Guan Z, Chang L, Chen Y, Yeh S, Chang C. ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway. Cancer Res. 2014 Aug 15;74(16):4420-30. doi: 10.1158/0008-5472.CAN-13-2681. Epub 2014 Jun 12. PubMed PMID: 24924778.

5: Izumi K, Chang C. Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression. Oncoimmunology. 2013 Dec 1;2(12):e26853. Epub 2013 Oct 22. PubMed PMID: 24498558; PubMed Central PMCID: PMC3902114.

6: Soh SF, Huang CK, Lee SO, Xu D, Yeh S, Li J, Yong EL, Gong Y, Chang C. Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal. 2014 Jan;88:117-22. doi: 10.1016/j.jpba.2013.08.020. Epub 2013 Aug 27. PubMed PMID: 24042123; PubMed Central PMCID: PMC3856572.

7: Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013 Aug 8;4:e764. doi: 10.1038/cddis.2013.270. PubMed PMID: 23928703; PubMed Central PMCID: PMC3763432.

8: Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S, Chang C. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem. 2013 Jul 5;288(27):19359-69. doi: 10.1074/jbc.M113.477216. Epub 2013 May 16. PubMed PMID: 23687298; PubMed Central PMCID: PMC3707641.

9: Lai KP, Huang CK, Chang YJ, Chung CY, Yamashita S, Li L, Lee SO, Yeh S, Chang C. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013 Feb;182(2):460-73. doi: 10.1016/j.ajpath.2012.10.029. Epub 2012 Dec 4. PubMed PMID: 23219429; PubMed Central PMCID: PMC3562731.

10: Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, Yeh S, Chang C. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia. 2012 Jan;14(1):74-83. PubMed PMID: 22355276; PubMed Central PMCID: PMC3281944.

11: Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, Miyamoto H, Merry DE, Sobue G, Chen LM, Chang SS, Chang C. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med. 2007 Mar;13(3):348-53. Epub 2007 Mar 4. PubMed PMID: 17334372.